Nuclease-dendrimer formulations for covid-19 and broad spectrum antiviral therapies and prophylaxis

In various embodiments, a composition in which a nuclease is formulated with a dendrimer is used, in a pharmaceutically effective dose, as a therapeutic agent for coronaviruses and broad spectrum viruses, such as HCoV-OC43, SARS-CoV-2 (covid-19). When cationized nuclease is mixed and/or compounded w...

Full description

Saved in:
Bibliographic Details
Main Authors RUDIN LEONID IVANOVICH, SU XIN
Format Patent
LanguageChinese
English
Published 28.07.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:In various embodiments, a composition in which a nuclease is formulated with a dendrimer is used, in a pharmaceutically effective dose, as a therapeutic agent for coronaviruses and broad spectrum viruses, such as HCoV-OC43, SARS-CoV-2 (covid-19). When cationized nuclease is mixed and/or compounded with dendrimers, an unexpected positive dendrimer effect appears. The positive dendritic macromolecule effect shows that the positive dendritic macromolecule is highly effective for catalyzing the antiviral RNA enzyme characteristic. In various embodiments, the composition of a cationized nuclease in combination with a dendrimer demonstrates such a synergistic amplification of the antiviral effectiveness and is used as a therapeutic agent against the coronavirus HCoV-OC43, SARS-CoV-2 and a broad spectrum of viruses in pharmaceutically effective doses. Example formulations that exhibit a positive dendritic effect are cationized RNAase A mixed and/or complexed with the second generation PAMAM dendrimers. 在各个实施例中，核酸酶与树
Bibliography:Application Number: CN202180068571